Introducing the Next Generation
Cancer Treatment

TAE Life Sciences is developing breakthrough technology for the clinical investigation of Boron Neutron Capture Therapy (BNCT) to provide a treatment option for patients with malignancies that are difficult to treat through traditional methods, such as head, neck and brain cancers. Our proprietary accelerator-based BNCT platform will combine two well-known modalities - biological targeting and radiation therapy - for precision treatment at the cellular level. TAE Life Sciences will bring this promising technology to the hospital setting, where it has previously been inaccessible.

Benefits of TAE Life Sciences BNCT

Biologically
Targeted

Tumor cells absorb a safe, boron-based vector drug that, when combined with neutrons, reacts to preferentially kill those cells while limiting damage to healthy tissue.

Precision
Engineered

Our proprietary accelerator-based neutron beam will have no moving parts and will be tunable, which will help support patient-specific treatments.

Patient
Friendly

Boron Neutron Capture Therapy (BNCT) is typically delivered in one or two treatment sessions, limits damage to healthy tissue and has been shown in some clinical studies to improve quality of life.1

Our Neutron Source

TAE Life Sciences is developing a state-of-the-art BNCT platform, the heart of which is an accelerator-based neutron source that is compact, cost-effective and precision engineered for BNCT delivery.

* The device being developed by TAE Life Sciences is for investigational use only and has not been approved for sale or commercial use.

Clinical Partners

We are looking to partner with hospitals and research institutions to initiate clinical trials to validate the next generation of BNCT.

Investor Relations

TAE Life Sciences is interested in speaking with potential investors whose charter aligns with our mission.

About Boron Neutron Capture Therapy

BNCT is a multi-step combination therapy. A cancer patient is first administered a boron target drug that preferentially binds to and carries non-toxic boron-10 to malignant cells. The tumor tissue is then showered with a beam of low energy neutrons at a level and spectrum optimal for reaction with the boron-10.

This reaction, inside the cells, emits charged particles that destroy the cell while limiting damage to surrounding healthy tissue without boron-10. Once the beam reacts with the boron in the cancer cells, the relative biological effectiveness (RBE) is significantly higher than in most other forms of radiation therapy.2

This secondary radiation reaction, with cellular-level precision, spares more healthy tissue and can potentially treat cancers that otherwise have few treatment options due to their proximity to critical tissue.1